Evidence map›Paper›PMID 39446266›Full record

ArticleAIDS and behavior2025

Hoping to Adhere? Examining the Relationship Between Hope and Pre-exposure Prophylaxis Willingness, Adherence, and Persistence Among Young Women in South Africa and Zimbabwe (HPTN 082).

Margaret W Gichane, Jennifer Velloza, Sybil Hosek, Geetha Beauchamp, Peter Anderson, Sinead Delany-Moretlwe, Connie Celum, and the HPTN 082 Study Team

Abstract read
In one paragraph

Article in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Margaret W GichaneDepartment of Obstetrics, Gynecology & Reproductive Sciences, Advancing New Standards in Reproductive Health, University of California, San Francisco, Oakland, CA, USA. waru.gichane@ucsf.edu.ORCID https://orcid.org/0000-0001-8499-154X
Jennifer VellozaDivision of Global Health and Infectious Disease Epidemiology, University of California San Francisco, San Francisco, USA.
Sybil HosekDepartment of Medicine, University of Illinois Chicago, Chicago, USA.
Geetha BeauchampFred Hutchinson Cancer Center, Seattle, USA.
Peter AndersonUniversity of Colorado Denver - Anschutz Medical Campus, Denver, USA.
Sinead Delany-MoretlweWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Connie CelumDepartments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, USA.
and the HPTN 082 Study Team

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
HIV Prevention trials Network (HPTN) Coordinating and Operations CenterU01AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI VERMUND, STEN H. · 2006 to 2010
$72.7M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Units for HIV/AIDS Clinical Trials NetworksU01AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI SANNE, IAN MATTHIAS · 2007 to 2011
$24.2M
Research Continuity During Parental LeaveK01MH134775 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Margaret Gichane · 2023 to 2026
$745k
National Institute of Allergy and Infectious Diseases UM1AI068613National Institute of Allergy and Infectious Diseases UM1AI068617National Institute of Allergy and Infectious Diseases UM1AI068619NIAID NIH HHS U01 AI068619NIAID NIH HHS U01 AI069463NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069463NIMH NIH HHS K01 MH134775NIMH NIH HHS K01MH134775
6 · The paper itself

Abstract

Hope is a powerful psychological construct which is linked to positive health. Greater hope is associated with improved antiretroviral therapy adherence; however, less is known about the impact of hope on oral pre-exposure prophylaxis (PrEP) outcomes. HIV Prevention Trials Network 082, was an open-label PrEP study among young women (ages 16-25) in South Africa and Zimbabwe. Hope was measured at baseline and follow-up using a subset of the Hope for the Future Scale (score range 6-24) and PrEP willingness was measured using a subscale of the HIV Prevention Readiness Measure (score range 6-30). Intracellular tenofovir-diphosphate (TFV-DP) concentrations were obtained from dried blood spot samples at weeks 13, 26, and 52; high PrEP adherence was defined as TFV-DP concentrations ≥ 700 fmol/punch. Persistence was defined as TFV-DP > 16 fmol/punch at weeks 26 and 52. Linear regression and generalized estimating equations were used to assess the relationship between hope and PrEP willingness, adherence, and persistence. The median age of participants (n = 432) was 21 years (interquartile range [IQR]: 19-22). The mean hope score at baseline was 21.0 (SD = 3.4). Although hope was positively associated with PrEP willingness (β = 0.22, 95% CI 0.15, 0.37), it was not associated with high PrEP adherence (aRR = 1.00, 95% CI 0.96, 1.05), or persistence at follow-up (aRR = 1.02, 95% CI 0.99, 1.05). While cultivating hope may be an important strategy in building willingness to take oral PrEP, it may not be enough to sustain PrEP adherence or persistence.

Indexed as

Anti-HIV AgentsHIV InfectionsHopeMedication AdherencePre-Exposure ProphylaxisAdenineAdolescentAdultFemaleHumansOrganophosphatesSouth AfricaTenofovirYoung AdultZimbabweAdenineAnti-HIV AgentsOrganophosphatesTenofovirtenofovir diphosphateAfricaHopePrEP adherencePrEP persistenceYoung women

Identifiers

PMID39446266
PMCPMC11814051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.